Statements (118)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:depression
gptkb:brand |
| gptkbp:approves |
gptkb:2015
schizophrenia bipolar disorder |
| gptkbp:brand |
gptkb:cariprazine
|
| gptkbp:class |
atypical antipsychotic
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:clinical_use |
acute episodes
treatment of schizophrenia long-term management maintenance treatment of bipolar disorder treatment of manic or mixed episodes of bipolar disorder treatment of manic or mixed episodes treatment of depressive episodes in bipolar disorder |
| gptkbp:contraindication |
severe hepatic impairment
lactation severe cardiovascular disease hypersensitivity to cariprazine |
| gptkbp:controlled_substance |
No
|
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| gptkbp:dosage_form |
gptkb:capsule
3 mg 1.5 mg 4.5 mg |
| gptkbp:drug_interactions |
MAO inhibitors
CYP3 A4 inducers CYP3 A4 inhibitors |
| gptkbp:duration |
short-term
long-term as prescribed by physician |
| gptkbp:effective_date |
2015-09-17
|
| gptkbp:financial_support |
avoid alcohol
monitor for mood changes do not discontinue abruptly |
| gptkbp:form |
gptkb:capsule
|
| gptkbp:formulation |
extended-release
|
| gptkbp:healthcare |
gptkb:Yes
yes |
| https://www.w3.org/2000/01/rdf-schema#label |
Vraylar
|
| gptkbp:ingredients |
gptkb:cariprazine
|
| gptkbp:invention |
gptkb:Abb_Vie
2026-09-17 |
| gptkbp:is_monitored_by |
gptkb:weight
blood pressure blood glucose lipid levels |
| gptkbp:manufacturer |
gptkb:Abb_Vie
|
| gptkbp:market_position |
available
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States Vraylar brand name |
| gptkbp:mechanism_of_action |
dopamine D2 receptor partial agonist
dopamine D3 and D2 receptor partial agonist serotonin 5-HT1 A receptor partial agonist serotonin 5-HT2 A receptor antagonist serotonin 5-HT1 A receptor agonist |
| gptkbp:name |
not on WHO Essential Medicines List
|
| gptkbp:packaging |
blister pack
|
| gptkbp:patient_population |
adults
adolescents |
| gptkbp:previous_name |
no
|
| gptkbp:price |
varies by region
|
| gptkbp:provides_guidance_on |
included in treatment guidelines
follow prescribing information consider patient history evaluate for metabolic syndrome |
| gptkbp:requires |
gptkb:true
available online prescription only |
| gptkbp:research |
ongoing
|
| gptkbp:research_focus |
safety profile
long-term efficacy comparative effectiveness |
| gptkbp:route_of_administration |
oral
|
| gptkbp:service_frequency |
once daily
|
| gptkbp:side_effect |
anxiety
fatigue headache nausea weight loss metabolic syndrome seizures restlessness drowsiness insomnia cardiovascular events constipation dry mouth weight gain blurred vision sedation hyperlipidemia sexual dysfunction tachycardia agitation hyperglycemia extrapyramidal symptoms akathisia neuroleptic malignant syndrome tardive dyskinesia orthostatic hypotension elevated prolactin levels |
| gptkbp:storage |
room temperature
protected from light protected from moisture |
| gptkbp:strength |
6 mg
3 mg 1.5 mg 4.5 mg |
| gptkbp:used_for |
schizophrenia
bipolar disorder treatment of schizophrenia treatment of bipolar disorder |
| gptkbp:bfsParent |
gptkb:Neurocrine_Biosciences
|
| gptkbp:bfsLayer |
5
|